LSE - Delayed Quote GBp
Fusion Antibodies plc (FAB.L)
6.80
-0.68
(-9.09%)
At close: April 25 at 6:32:20 PM GMT+1
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
1,136
1,136
2,901
4,799
4,165
Cost of Revenue
1,181
1,181
2,327
2,333
2,141
Gross Profit
-45
-45
574
2,466
2,024
Operating Expense
2,242
2,242
3,432
3,791
3,273
Operating Income
-2,287
-2,287
-2,858
-1,325
-1,249
Net Non Operating Interest Income Expense
-2
-2
-1
-8
-15
Pretax Income
-2,289
-2,289
-2,859
-1,333
-1,264
Tax Provision
-63
-63
-263
-133
1,635
Net Income Common Stockholders
-2,226
-2,226
-2,596
-1,200
-2,899
Diluted NI Available to Com Stockholders
-2,226
-2,226
-2,596
-1,200
-2,899
Basic EPS
-0.04
--
-0.10
-0.05
-0.11
Diluted EPS
-0.04
--
-0.10
-0.05
-0.11
Basic Average Shares
55,556.02
--
26,014.95
25,945.78
25,458.76
Diluted Average Shares
95,365.56
--
26,014.95
25,945.78
25,458.76
Total Operating Income as Reported
-2,288
-2,288
-2,858
-1,325
-1,249
Total Expenses
3,423
3,423
5,759
6,124
5,414
Net Income from Continuing & Discontinued Operation
-2,226
-2,226
-2,596
-1,200
-2,899
Normalized Income
-2,226
-2,226
-2,596
-1,200
-2,899
Interest Income
3
3
3
1
3
Interest Expense
5
5
4
9
18
Net Interest Income
-2
-2
-1
-8
-15
EBIT
-2,284
-2,284
-2,855
-1,324
-1,246
EBITDA
-2,064
-2,064
-2,483
-573
-532
Reconciled Cost of Revenue
1,181
1,181
2,327
2,333
2,141
Reconciled Depreciation
220
220
372
751
714
Net Income from Continuing Operation Net Minority Interest
-2,226
-2,226
-2,596
-1,200
-2,899
Normalized EBITDA
-2,064
-2,064
-2,483
-573
-532
Tax Rate for Calcs
0
0
0
0
0
3/31/2021 - 12/18/2017
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
2QV0.F Chemomab Therapeutics Ltd.
1.0900
+2.83%
PBN.F Alterity Therapeutics Limited
0.0045
+12.50%
6XY.F HBM Holdings Limited
0.9000
+5.88%
TRMED.OL Thor Medical ASA
2.4000
-2.24%
ELIC.ST Elicera Therapeutics AB (publ)
4.3500
+13.73%
TRX.L Tissue Regenix Group plc
35.00
+0.57%
FARN.L Faron Pharmaceuticals Oy
202.00
-0.25%
BIOVIC-B.ST Biovica International AB (publ)
0.6980
+9.06%
MEDCL.PA MedinCell S.A.
14.97
+0.13%
VVY.AS Vivoryon Therapeutics N.V.
1.7760
-1.88%